Vaxxinity, Inc. (VAXX)

0,1042 -0,0104 (-9,08%) Börsenschluss: 04:00PM EDT

Vaxxinity, Inc.

505 Odyssey Way
Merritt Island, FL 32953
United States
(254)244-5739
https://www.vaxxinity.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 57

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Louis Garfield Reese IV	Co-Founder & Executive Chairman of the Board	83,28k	N/A	1982
Ms. Mei Mei Hu J.D.	CEO & Director	551,73k	N/A	1983
Dr. Jean-Cosme Dodart Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Sumita Ray J.D.	Chief Legal & Administrative Officer	N/A	N/A	1974
Mr. Jon Harrison	Chief Government Officer	N/A	N/A	N/A
Mr. Mark Joinnides MSE	Chief of Staff	N/A	N/A	N/A
Ms. Amy B. Fix M.B.A., M.S., R.A.C.	Head of Regulatory	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Corporate Governance

Vaxxinity, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 9, Shareholderrechte: 10, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.